PER percheron therapeutics limited

10.0%

0.9¢

Ann: Phase IIb study of ATL1102 in DMD completes recruitment, page-139

First 139 Last

Share
Profile

Follow
Akki

35,790 Posts.

555

20/07/24

18:33

Post #: 74842224
Share

Originally posted by imperatore ↑

Akki you are just funny. So in your way of thinking if somebody get to same conclusion that do not match with your way of thinking they must be the same person…..you just laughable.
Fact is that yes you may not have anything against management but for sure I haven’t seen you posting anything positive ref PER and/or drug’s pipeline. Is that possible there nothing you like in the PER story? Then why are you here?
And no I am not insulsa and don’t even know him/her so put your “adventurous” extra sense on rest.
P.S. if by a very unexpected motive you, in your high intellectual mind, come across something positive about PER would you be kind enough to share with all of us here?

Expand

i think the problem probably is you only like what you want to see

you hate bod & management not delivering ?

and akki’s posts are never “positive” ….

so factual and reality = negative ?

Itsgas and his 13 xmas’s etc for CEO ?

Last edited by Akki: 20/07/24

PER Price at posting: 8.0¢ Sentiment: None Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

BOE

Boss extends June win streak with boosted Alta Mesa extraction rates

'Not possible' to port renewable gas: ACCC takes AGN to court

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

First 139 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.9¢		Change -0.001(10.0%)		Mkt cap ! $9.786M

Open	High	Low	Value	Volume
1.0¢	1.0¢	0.9¢	$94.66K	10.09M

Buyers (Bids)

No.	Vol.	Price($)
4	661860	0.9¢

Sellers (Offers)

Price($)	Vol.	No.
1.0¢	1588275	6

View Market Depth

No.	Vol.	Price($)
4	661860	0.009
7	3873000	0.008
2	1142857	0.007
2	1999997	0.006
2	3200000	0.005

Price($)	Vol.	No.
0.010	1588275	6
0.011	2500000	6
0.012	2758324	6
0.013	691461	3
0.014	1572000	3

Last trade - 15.52pm 27/06/2025 (20 minute delay)

PER (ASX) Chart

Ann: Phase IIb study of ATL1102 in DMD completes recruitment, page-139

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Boss extends June win streak with boosted Alta Mesa extraction rates

'Not possible' to port renewable gas: ACCC takes AGN to court

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Phase IIb study of ATL1102 in DMD completes recruitment, page-139

Top Stories

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Boss extends June win streak with boosted Alta Mesa extraction rates

'Not possible' to port renewable gas: ACCC takes AGN to court

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News